Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990677 · ClinicalTrials.gov registry record · NA
Eplerenone for the Treatment of Central Serous Chorioretinopathy
A NA study of Central Serous Chorioretinopathy, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
- 10
- Study locations
NCT01990677 is a NA study of Central Serous Chorioretinopathy that has completed, run by Wills Eye. The registered enrollment target is 108 participants, above the 68-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (59% higher). The trial reports 10 study locations across 2 states.
The verdict
NCT01990677, a NA study of Central Serous Chorioretinopathy, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
- 10
- Study locations
Study Summary
To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 25mg Eplerenone
Study Locations (10)
Pennsylvania
- Mid Atlantic Retina - Bala-Cynwyd
- Mid Atlantic Retina - Bethlehem
- Mid Atlantic Retina - Huntingdon Valley
- Mid Atlantic Retina - Lansdale
- Mid Atlantic Retina - New Wilmington
- Mid Atlantic Retina - Newtown Square
- Mid Atlantic Retina - Plymouth Meeting
New Jersey
- Mid Atlantic Retina - Cherry Hill
- Mid Atlantic Retina - Marlton
- Mid Atlantic Retina - Mays Landing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01990677
The ClinicalTrials.gov registry entry for NCT01990677 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 68-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (59% higher). The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01990677 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01990677 about?
NCT01990677 is a clinical study titled "Eplerenone for the Treatment of Central Serous Chorioretinopathy". To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
What is the current status of trial NCT01990677?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2013-10. Estimated completion is 2015-05.
What conditions does trial NCT01990677 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT01990677?
The interventions under investigation include: Placebo (DRUG), 25mg Eplerenone (DRUG).
Who is sponsoring clinical trial NCT01990677?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01990677 being conducted?
This trial has 10 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.